The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated efficacy and safety results of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM).
 
Masa Lasica
No Relationships to Disclose
 
Sikander Ailawadhi
Consulting or Advisory Role - Amgen (Inst); Beigene; BMS (Inst); Cellectar (Inst); GlaxoSmithKline; Janssen (Inst); Pharmacyclics (Inst); Regeneron; Sanofi; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Ascentage Pharma (Inst); BMS (Inst); Cellectar (Inst); GlaxoSmithKline (Inst); Janssen Biotech (Inst); Pharmacyclics (Inst); Sanofi (Inst)
 
Chengcheng Fu
No Relationships to Disclose
 
Sheeba K. Thomas
No Relationships to Disclose
 
Depei Wu
No Relationships to Disclose
 
Shuhua Yi
No Relationships to Disclose
 
Tanya Siddiqi
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Celgene; Kite, a Gilead company
Speakers' Bureau - AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene
Research Funding - Acerta Pharma (Inst); Ascentage Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb/Sanofi (Inst); Celgene (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); Oncternal Therapeutics (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
 
Qingsong Yin
No Relationships to Disclose
 
John N. Allan
No Relationships to Disclose
 
Wenming Chen
No Relationships to Disclose
 
Jeffrey V Matous
Consulting or Advisory Role - BeiGene; Pharmacyclics
 
Ru Feng
No Relationships to Disclose
 
Zi Chen
Employment - Ascentage Pharma
Stock and Other Ownership Interests - Ascentage Pharma
 
Min Yu
Employment - Ascentage Pharma
Stock and Other Ownership Interests - Ascentage Pharma
 
Mingyu Li
Employment - Ascentage Pharma
Stock and Other Ownership Interests - Ascentage Pharma
 
Zicong He
Employment - Ascentage Pharma Pty Ltd.
Stock and Other Ownership Interests - Ascentage Pharma
 
Mohammad Ahmad
Employment - Ascentage Pharma
Stock and Other Ownership Interests - Ascentage Pharma
 
Hengbang Wang
Employment - Ascentage Pharma
Stock and Other Ownership Interests - Ascentage Pharma
 
Asher Alban Akmal Chanan-Khan
Leadership - Cellectar; STARTON Therapeutics
Stock and Other Ownership Interests - Cellectar; Matthew & Asher Inc.; NanoDev Therapeutics; STARTON Therapeutics
Honoraria - Ascentage Pharma; BeiGene
Consulting or Advisory Role - Ascentage Pharma Group
Research Funding - Ascentage Pharma
Patents, Royalties, Other Intellectual Property - Patent on PSMB9 biomarker; Tabi Vaccine
 
Yifan Zhai
Employment - Ascentage Pharma; Ascentage Pharma
Leadership - Ascentage Pharma; Ascentage Pharma
Stock and Other Ownership Interests - Ascentage Pharma